Company Overview and News

 
NAV & Investment in AgeX Therapeutics Inc.

2017-07-20 londonstockexchange
The unaudited Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2017 was 9.35 pence per share, including un-invested cash of £875,885. The portfolio is valued under IFRS at bid price.

 
Results for the Year ended 31 March 2017

2017-07-07 londonstockexchange
·      The Company acquired three investments in the year, including a significant investment in a Canadian medical marijuana company, and successfully disposed of one investment post year end. Further details of these investments are set out at in the Report of the Chief Executive Officer

 
Net Asset Value(s)

2017-04-12 londonstockexchange
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2017 was 10.56 pence per share, including un-invested cash of £3,285.  The portfolio is valued under IFRS at bid price.

 
Update on Potential Acquisition

2017-04-06 londonstockexchange
On 6 October 2016, the Board of Life Science Developments Limited (the "Company" or "LIFE") announced that it had signed a non-binding Term Sheet to acquire up to 100% of the issued share capital of The Diabetic Boot Company Limited ("DBC") for new shares in LIFE (the "Acquisition").

 
Half-year Report

2017-03-29 londonstockexchange
The Board of Port Erin, the AIM quoted company focused on investing in the biotechnology and

 
Net Asset Value(s)

2017-01-12 londonstockexchange
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2016 was 11.13 pence per share, including un-invested cash of £66,642.  The portfolio is valued under IFRS at bid price.

 
Half-year Report

2016-12-20 londonstockexchange
·      The Company has completed two investments during the period. Further details of these investments are set out at the Company's website and in the Co-Chairman's Statement in this report.

 
How Brazilian Resources' Strategy Translates To Upside Potential

2016-12-09 seekingalpha
Brazil Resources Inc. is undervalued at its current price, and has proven resources and real growth potential.

 
Regent Pacific mutates into selling pharmaceuticals to save sagging fortunes

2016-11-24 scmp
Company to begin selling Fortacin spray-on treatment for men’s premature ejaculation in Hong Kong by the end of 2017

 
Total Voting Rights

2016-05-04 londonstockexchange
Following the Placing as announced on 4 April 2016, the Company announces the following significant shareholdings in the Company's Ordinary Shares of 20 pence each (the "Ordinary Shares"):

 
Investee Company Update

2016-04-22 londonstockexchange
FastForward notes that its investee company, Diabetic Boot Company Limited ("DBC"), is seeking to raise up to £3.5 million from its shareholders by issuing new ordinary shares at a price of £23 per share. New shareholders will also receive warrants in the ratio of one warrant for each two new shares issued, the warrant is exercisable at £26.45 per share within five years ("Warrants"). The Company is not intending to invest in this issue.

 
Interim Results for the six months to 31 Dec 2015

2016-03-17 londonstockexchange
The Board of Port Erin, the AIM quoted company focused on investing in the biotechnology and

 
Expected timetable for suspension and de-listing

2016-02-11 londonstockexchange
Plethora Solutions Holdings PLC (AIM: PLE) would like to draw the attention of its shareholders to certain dates in the expected timetable of events set out in the scheme document published by the Company, as previously announced on 4 February 2016, in relation to the recommended acquisition of Plethora by Regent Pacific Group Limited (the "Scheme Document"). The Scheme Document is available on the Company's website at http://www.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...